Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES PLIMPTON

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1891777835
CMS profile
267685
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$63.56

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $63.56 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Hologic Sales and Service, LLC $22.45 1
Evofem Biosciences, Inc. $21.77 1
OptumHealth Care Solutions, LLC $19.34 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES PLIMPTON

NPI 1891777835 · CMS profile ID 267685

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891777835?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891777835?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891777835?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1891777835?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $63.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Hologic Sales and Service, LLC $22.4508/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182612203 CMS
Evofem Biosciences, Inc. $21.7705/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253953612 CMS
OptumHealth Care Solutions, LLC $19.3403/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250015558 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,037.66 8
PY2020 $4,550.00 1
PY2024 $164.80 3
PY2025 $63.56 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $280,140.77 30
PY2024 Principal investigator $631,342.46 58
PY2023 Principal investigator $604,319.86 129
PY2022 Principal investigator $1,688,412.68 133
PY2021 Principal investigator $3,601,852.60 159
PY2020 Principal investigator $853,852.30 65
PY2019 Principal investigator $195,210.58 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

159 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $35,016.63 12/29/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832569380
Principal investigator 1 Janssen Pharmaceuticals, Inc $12,692.00 12/28/2021 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787573681
Principal investigator 1 PFIZER INC. $1,322.64 12/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832568523
Principal investigator 1 PFIZER INC. $5,237.43 12/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832569371
Principal investigator 2 ModernaTX, Inc. $239,830.31 12/22/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941561
Principal investigator 2 ModernaTX, Inc. $8,027.50 12/22/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946591
Principal investigator 3 ModernaTX, Inc. $88,792.73 12/22/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946593
Principal investigator 1 GlaxoSmithKline, LLC. $2,235.42 12/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499131
Principal investigator 1 GlaxoSmithKline, LLC. $24,418.50 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809492963
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494039
Principal investigator 1 GlaxoSmithKline, LLC. $2,633.40 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494071
Principal investigator 1 GlaxoSmithKline, LLC. $3,128.40 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809520093
Principal investigator 1 GlaxoSmithKline, LLC. $2,261.16 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809520099
Principal investigator 1 GlaxoSmithKline, LLC. $2,922.48 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809537801
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809539063
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.08 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809539085
Principal investigator 1 GlaxoSmithKline, LLC. $290.07 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809539111
Principal investigator 1 ModernaTX, Inc. $113,964.23 12/01/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860940415
Principal investigator 2 ModernaTX, Inc. $3,900.00 12/01/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946589
Principal investigator 3 ModernaTX, Inc. $295,461.40 12/01/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946599
Principal investigator 1 PFIZER INC. $15,522.21 11/27/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832703051
Principal investigator 1 GlaxoSmithKline, LLC. $2,278.98 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494049
Principal investigator 1 GlaxoSmithKline, LLC. $2,762.10 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499161
Principal investigator 1 GlaxoSmithKline, LLC. $1,332.54 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809517639
Principal investigator 1 GlaxoSmithKline, LLC. $3,346.20 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809539057
Principal investigator 1 GlaxoSmithKline, LLC. $3,065.04 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809539081
Principal investigator 3 ModernaTX, Inc. $86,331.25 11/24/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941557
Principal investigator 2 ModernaTX, Inc. $223,325.05 11/24/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941559
Principal investigator 1 PFIZER INC. $148,654.11 11/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832816621
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,252.00 11/22/2021 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787573668
Principal investigator 1 PFIZER INC. $1,417.20 11/22/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832526905
Principal investigator 1 PFIZER INC. $802.49 11/22/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832528007
Principal investigator 1 GlaxoSmithKline, LLC. $5,780.61 11/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809517645
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.28 11/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526023
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 11/17/2021 Non-covered Recipient Entity
Medpharmics,LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838361129
Principal investigator 1 PFIZER INC. $1,560.24 11/10/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832670297
Principal investigator 1 PFIZER INC. $28,416.30 11/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832796479
Principal investigator 1 GlaxoSmithKline, LLC. $2,278.98 11/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490503
Principal investigator 1 GlaxoSmithKline, LLC. $2,169.09 11/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809495171
Principal investigator 2 ModernaTX, Inc. $358,628.63 10/27/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860940417
Principal investigator 2 ModernaTX, Inc. $168,058.25 10/27/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946595
Principal investigator 1 ModernaTX, Inc. $218,678.85 10/27/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860946597
Principal investigator 1 PFIZER INC. $18,893.49 10/26/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832800885
Principal investigator 1 GlaxoSmithKline, LLC. $1,525.59 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809507057
Principal investigator 1 GlaxoSmithKline, LLC. $8,675.37 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809543437
Principal investigator 1 PFIZER INC. $7,277.16 10/14/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832879119
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494089
Principal investigator 1 GlaxoSmithKline, LLC. $1,596.87 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809501801
Principal investigator 1 GlaxoSmithKline, LLC. $15,950.00 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809517113
Principal investigator 1 PFIZER INC. $30,487.05 10/08/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832755877
Principal investigator 1 PFIZER INC. $3,763.32 10/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832670814
Principal investigator 1 PFIZER INC. $736.56 09/29/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671271
Principal investigator 1 GlaxoSmithKline, LLC. $3,051.18 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809504613
Principal investigator 1 GlaxoSmithKline, LLC. $4,112.46 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809540169
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.64 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809540175
Principal investigator 1 ModernaTX, Inc. $101,172.08 09/22/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941835
Principal investigator 1 PFIZER INC. $3,752.10 09/22/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832894093
Principal investigator 1 PFIZER INC. $2,868.36 09/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671251
Principal investigator 1 GlaxoSmithKline, LLC. $4,112.46 09/08/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809501807
Principal investigator 1 PFIZER INC. $350.00 09/04/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832710399
Principal investigator 1 PFIZER INC. $34,036.20 09/04/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832776811
Principal investigator 1 PFIZER INC. $2,790.48 09/01/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832667445
Principal investigator 1 ModernaTX, Inc. $13,949.33 08/25/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941833
Principal investigator 1 PFIZER INC. $914.76 08/25/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832670823
Principal investigator 1 GlaxoSmithKline, LLC. $1,976.04 08/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490495
Principal investigator 1 GlaxoSmithKline, LLC. $3,823.38 08/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499913
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 08/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526017
Principal investigator 1 PFIZER INC. $29,125.80 08/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832705655
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $300.00 08/19/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026897
Principal investigator 1 GlaxoSmithKline, LLC. $1,525.59 08/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490477
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,995.00 08/11/2021 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787573519
Principal investigator 1 GlaxoSmithKline, LLC. $3,862.98 08/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489245
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.08 08/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809527265
Principal investigator 1 PFIZER INC. $190,861.80 08/06/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832855659
Principal investigator 3 ModernaTX, Inc. $4,631.25 08/04/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941831
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 08/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525963
Principal investigator 2 ModernaTX, Inc. $9,299.55 08/02/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941829
Principal investigator 1 PFIZER INC. $1,071.84 07/31/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832667899
Principal investigator 1 GlaxoSmithKline, LLC. $4,801.50 07/27/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499823
Principal investigator 1 GlaxoSmithKline, LLC. $2,053.26 07/27/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499925
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 07/27/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809527252
Principal investigator 1 Janssen Pharmaceuticals, Inc $11,500.00 07/23/2021 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787573509
Principal investigator 2 ModernaTX, Inc. $1,000.00 07/23/2021 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 860941827
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.89 07/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489243
Principal investigator 1 GlaxoSmithKline, LLC. $1,106.82 07/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499931
Principal investigator 1 PFIZER INC. $31,157.00 07/20/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832738995
Principal investigator 1 PFIZER INC. $2,163.48 07/17/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671037
Principal investigator 1 GlaxoSmithKline, LLC. $2,685.87 07/14/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490499
Principal investigator 1 GlaxoSmithKline, LLC. $2,286.90 07/14/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499919
Principal investigator 1 PFIZER INC. $914.76 07/14/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671027
Principal investigator 1 GlaxoSmithKline, LLC. $1,976.04 07/07/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489279
Principal investigator 1 PFIZER INC. $4,605.48 07/07/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832667455
Principal investigator 1 GlaxoSmithKline, LLC. $1,673.10 07/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809527259
Principal investigator 1 PFIZER INC. $860.64 06/29/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832897867
Principal investigator 1 GlaxoSmithKline, LLC. $978.12 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489239
Principal investigator 1 GlaxoSmithKline, LLC. $2,440.35 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499949
Principal investigator 1 GlaxoSmithKline, LLC. $8,559.54 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809500377
Principal investigator 1 GlaxoSmithKline, LLC. $1,106.82 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526035
Principal investigator 1 PFIZER INC. $2,163.48 06/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671017
Principal investigator 1 PFIZER INC. $49,041.30 06/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832801557
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,222.36 06/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025209
Principal investigator 1 PFIZER INC. $4,605.48 06/11/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832671261
Principal investigator 1 PFIZER INC. $1,151.04 06/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832809023
Principal investigator 1 PFIZER INC. $1,200.00 06/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832837513
Principal investigator 1 PFIZER INC. $172.60 06/02/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832690907
Principal investigator 1 Abbott Laboratories $8,000.00 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Alinity m HR HPV Specimen Collection Study from Women Undergoing Routine Cervical cancer Screening No dispute reported 06/30/2026 827576657
Principal investigator 1 GlaxoSmithKline, LLC. $4,350.00 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809484821
Principal investigator 1 GlaxoSmithKline, LLC. $6,943.86 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489275
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.00 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809491181
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809491183
Principal investigator 1 GlaxoSmithKline, LLC. $4,009.50 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526039
Principal investigator 1 GlaxoSmithKline, LLC. $2,832.39 05/26/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489241
Principal investigator 1 GlaxoSmithKline, LLC. $1,106.82 05/26/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490427
Principal investigator 1 GlaxoSmithKline, LLC. $2,084.94 05/26/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490467
Principal investigator 1 GlaxoSmithKline, LLC. $3,789.90 05/26/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809510937
Principal investigator 1 PFIZER INC. $158,337.30 05/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832874355
Principal investigator 1 GlaxoSmithKline, LLC. $1,924.56 05/19/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499817
Principal investigator 1 GlaxoSmithKline, LLC. $3,886.74 05/12/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490497
Principal investigator 1 GlaxoSmithKline, LLC. $1,737.45 05/12/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809500385
Principal investigator 1 GlaxoSmithKline, LLC. $14,999.49 05/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489277
Principal investigator 1 GlaxoSmithKline, LLC. $5,169.78 05/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490501
Principal investigator 1 GlaxoSmithKline, LLC. $1,778.40 05/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809510955
Principal investigator 1 GlaxoSmithKline, LLC. $3,726.36 05/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526011
Principal investigator 1 PFIZER INC. $5,016.00 04/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832695235
Principal investigator 1 GlaxoSmithKline, LLC. $290.07 04/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525957
Principal investigator 1 PFIZER INC. $1,151.04 04/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832917155
Principal investigator 1 PFIZER INC. $32.46 04/16/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832921137
Principal investigator 1 PFIZER INC. $66,184.80 04/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832819537
Principal investigator 1 GlaxoSmithKline, LLC. $1,123.20 04/07/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809484905
Principal investigator 1 GlaxoSmithKline, LLC. $2,407.68 03/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526005
Principal investigator 1 PFIZER INC. $13,850.00 03/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832667909
Principal investigator 1 PFIZER INC. $31,072.80 03/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832917033
Principal investigator 1 GlaxoSmithKline, LLC. $1,901.70 03/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809485427
Principal investigator 1 GlaxoSmithKline, LLC. $5,477.67 03/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499805
Principal investigator 1 GlaxoSmithKline, LLC. $3,391.74 03/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499937
Principal investigator 1 PFIZER INC. $172.60 03/17/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832718429
Principal investigator 1 PFIZER INC. $21.64 03/17/2021 Non-covered Recipient Entity
MedPharmics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832745573
Principal investigator 1 PFIZER INC. $13,496.00 03/15/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 948971117
Principal investigator 1 PFIZER INC. $18,748.62 03/13/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832879769
Principal investigator 1 GlaxoSmithKline, LLC. $7,003.26 03/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490475
Principal investigator 1 GlaxoSmithKline, LLC. $7,003.26 03/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499811
Principal investigator 1 GlaxoSmithKline, LLC. $3,019.50 03/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809499943
Principal investigator 1 SANOFI PASTEUR INC. $1,050.00 03/10/2021 Non-covered Recipient Entity
Medpharmics,LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 838360873
Principal investigator 1 PFIZER INC. $9,276.30 03/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832859789
Principal investigator 1 PFIZER INC. $1,943.04 02/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832825601
Principal investigator 1 GlaxoSmithKline, LLC. $5,477.67 02/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809489235
Principal investigator 1 PFIZER INC. $157,419.90 02/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832782189
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490471
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.63 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490473
Principal investigator 1 GlaxoSmithKline, LLC. $4,300.00 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809526029
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $724.68 02/11/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021805
Principal investigator 1 GlaxoSmithKline, LLC. $1,778.40 02/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809491149
Principal investigator 1 GlaxoSmithKline, LLC. $4,705.47 02/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525951
Principal investigator 1 PFIZER INC. $38,725.50 02/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832757713
Principal investigator 1 PFIZER INC. $6,556.50 02/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832798977
Principal investigator 1 GlaxoSmithKline, LLC. $38,862.00 02/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809510943
Principal investigator 1 PFIZER INC. $38,121.60 01/16/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832916253
Principal investigator 1 PFIZER INC. $59,891.70 01/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832875579
Principal investigator 1 PFIZER INC. $12,703.74 01/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832894103